Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome

Abstract

In this retrospective cohort, by far the most important reason for MMF dose reduction during the first post-transplantation year was hematologic. MMF dose reductions in ≥ 50% increased the risk of acute rejection but did not compromise graft survival.